Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Heavy Duty Batteries

<< Previous

Bullboard Posts

Next >>

Comment by Rockafellowon Dec 15, 2020 10:27am

81 Views

Post# 32108278

RE:Heavy Duty Batteries

More false news... .... Lithium batteries r on the way out due to new solid state fluoride anodes batteries in development that pack 5x more energy per weight so that EV cars will b able 2 go 1000 km before a recharge. Now that's progress-- period. I want a EV car that will take me from Toronto to Tampa on one charge r I won't buy one...... ...
Now what has this to do with this stock?????

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload